Generics - Antibiotics and Infectious diseases, North America, Noven Pharmaceuticals

Bayer in settlement over Cipro pricing

04-09-2013

A partial settlement has been reached in a US class action law suit involving the prescription antibiotic…

Antibiotics and Infectious diseasesBayerCiproGenericsLegalNorth AmericaPharmaceuticalPricing

$200+ billion annual opportunity in USA from using medicines more responsibly, IMS finds

20-06-2013

Avoidable costs of more than $200 billion are incurred each year in the US health care system as a result…

Antibiotics and Infectious diseasesDiabetesFinancialGenericsHealthcareNorth AmericaPharmaceutical

Mylan debuts generic Antara; FDA approves generics of Actavis' Suboxone, Lupin's Suprax and Zydus' Zantac

25-02-2013

US generic firm Mylan (Nasdaq: MYL) says its subsidiary Mylan Pharmaceuticals has begun shipping fenofibrate…

ActavisAntaraAntibiotics and Infectious diseasesCardio-vascularGastro-intestinalsGenericsLupinMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaRegulationSuboxoneSupraxZantacZydus Cadila

US FDA pulls 27 Ranbaxy ANDAs approvals under consent decree

23-08-2012

The Food and Drug Administration is withdrawing approval of 27 Abbreviated New Drug Applications (ANDAs)…

Antibiotics and Infectious diseasesDaiichi SankyoDiabetesGenericsNorth AmericaRanbaxy LaboratoriesRegulation

Teva settles Nuvigil patent litigation with Mylan, which debuts generic Doryx

01-05-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA), the world's largest generics companies, said…

Antibiotics and Infectious diseasesDoryxGenericsLegalMergers & AcquisitionsMylan LaboratoriesNeurologicalNorth AmericaNuvigilPatentsPharmaceuticalTeva Pharmaceutical IndustriesWarner Chilcott

ViroPharma stock plunges on bad news for Vancocin; Sanofi patents invalidated

11-04-2012

ViroPharma I (Nasdaq: VPHM) saw its shares plunge 19% to $23.25 yesterday after it announced that the…

Antibiotics and Infectious diseasesApotexGenericsHospiraLegalNorth AmericaOncologyPatentsPharmaceuticalRegulationSanofiTaxotereVancocinViroPharmaWatson Pharmaceuticals

Hospira challenges Cubist patents on Cubicin

10-02-2012

US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) says that it has received a Paragraph IV Notice Letter…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsGenericsHospiraNorth AmericaPatentsPharmaceuticalResearch

US hospital pharmacy and therapeutics committees decision-making process for antibiotics and antifungal therapies

15-11-2011

In addition to managing the hospital’s anti-infective formulary, hospital pharmacy and therapeutics…

Antibiotics and Infectious diseasesGenericsMarkets & MarketingNorth AmericaPharmaceutical

Back to top